» Authors » Winfried Brenner

Winfried Brenner

Explore the profile of Winfried Brenner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 159
Citations 2254
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang L, Haeckel A, Beindorff N, Poetzsch S, Mi H, Ni F, et al.
Int J Biol Macromol . 2025 Mar; 306(Pt 4):141679. PMID: 40037452
The virus protein CAV-Apoptin and its homologue HGV-Apoptin selectively kill cancer cells but are not suitable for systemic treatment. The aim was to develop Apoptin-based fusion proteins for intravenous application...
2.
Wedel F, Exarchopoulos T, Brenner W
Nuklearmedizin . 2024 Jan; 63(2):69-75. PMID: 38190997
Purpose: Radioiodine therapy (RIT) of benign thyroid diseases is an established therapy. This study aimed to identify factors predictive for outcome in patients with non-toxic goiter (NTG), unifocal (UFA), multifocal...
3.
Schmitz-Peiffer F, Lukas M, Mohan A, Albrecht J, Aschenbach J, Brenner W, et al.
EJNMMI Res . 2024 Jan; 14(1):4. PMID: 38180547
Background: The influence of anaesthetic depth and the potential influence of different anaesthetic beds and thus different handling procedures were investigated in 86 severe combined immunodeficient (SCID) mice using semi-stationary...
4.
Baitullina A, Claude G, Sucena S, Nisli E, Scholz C, Bhardwaj P, et al.
EJNMMI Radiopharm Chem . 2023 Nov; 8(1):40. PMID: 37982944
Background: Heterometallic gold metallacages are of great interest for the incorporation of several cations. Especially in nuclear medicine, those metallacages can serve as a platform for radionuclides relevant for imaging...
5.
Mohan A, Prasad S, Schmitz-Peiffer F, Lange C, Lukas M, Koziolek E, et al.
Endocr Relat Cancer . 2023 Nov; 31(1). PMID: 37943630
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation,...
6.
Balzer M, Spiecker F, Bluemel S, Amthauer H, Brenner W, Spreckelmeyer S
EJNMMI Radiopharm Chem . 2023 Nov; 8(1):37. PMID: 37930495
Background: Lu-radiopharmaceuticals can contain the metastable impurity [Lu]lutetium with a physical half-life of 160.4 days, in varying concentrations depending on the route of production of the radionuclidic precursor [Lu]lutetium. Due...
7.
Dejene E, Brenner W, Makowski M, Kolbitsch C
Phys Med Biol . 2023 Oct; 68(21). PMID: 37820640
. Physiological parameter estimation is affected by intrinsic ambiguity in the data such as noise and model inaccuracies. The aim of this work is to provide a deep learning framework...
8.
Rogasch J, Metzger G, Preisler M, Galler M, Thiele F, Brenner W, et al.
J Nucl Med . 2023 Sep; 64(12):1876-1879. PMID: 37709536
We evaluated whether the artificial intelligence chatbot ChatGPT can adequately answer patient questions related to [F]FDG PET/CT in common clinical indications before and after scanning. Thirteen questions regarding [F]FDG PET/CT...
9.
Lohmeier J, Radbruch H, Brenner W, Hamm B, Hansen B, Tietze A, et al.
Eur Radiol . 2023 Sep; 34(4):2487-2499. PMID: 37672058
Objectives: Differentiation between high-grade glioma (HGG) and post-treatment-related effects (PTRE) is challenging, but advanced imaging techniques were shown to provide benefit. We aim to investigate microstructure characteristics of metabolic compartments...
10.
Lohmeier J, Radbruch H, Brenner W, Hamm B, Tietze A, Makowski M
J Nucl Med . 2023 Aug; 64(11):1683-1689. PMID: 37652542
Molecular markers are of increasing importance for classifying, treating, and determining the prognosis for central nervous system tumors. Isocitrate dehydrogenase (IDH) is a critical regulator of glucose and amino acid...